ATE324113T1 - Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom - Google Patents

Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom

Info

Publication number
ATE324113T1
ATE324113T1 AT04016883T AT04016883T ATE324113T1 AT E324113 T1 ATE324113 T1 AT E324113T1 AT 04016883 T AT04016883 T AT 04016883T AT 04016883 T AT04016883 T AT 04016883T AT E324113 T1 ATE324113 T1 AT E324113T1
Authority
AT
Austria
Prior art keywords
xanthoma
silyl
dialkyl
treatment
phenol derivatives
Prior art date
Application number
AT04016883T
Other languages
English (en)
Inventor
Simon Jen Tan Mao
Mark Thirston Yates
Roger Alan Parker
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Application granted granted Critical
Publication of ATE324113T1 publication Critical patent/ATE324113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
AT04016883T 1993-12-10 1994-11-03 Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom ATE324113T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16528193A 1993-12-10 1993-12-10

Publications (1)

Publication Number Publication Date
ATE324113T1 true ATE324113T1 (de) 2006-05-15

Family

ID=22598245

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04016883T ATE324113T1 (de) 1993-12-10 1994-11-03 Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom
AT95901141T ATE285238T1 (de) 1993-12-10 1994-11-03 Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95901141T ATE285238T1 (de) 1993-12-10 1994-11-03 Verfahren zur senkung des serumcholesterinspiegels mit 2,6-dialkyl-4 silyl- phenol derivaten

Country Status (16)

Country Link
EP (3) EP1468693A3 (de)
JP (1) JPH09511222A (de)
CN (1) CN1092517C (de)
AT (2) ATE324113T1 (de)
AU (1) AU681731B2 (de)
CA (1) CA2177968C (de)
DE (2) DE69434720T2 (de)
DK (2) DK1468692T3 (de)
ES (2) ES2233937T3 (de)
HU (1) HU220761B1 (de)
IL (1) IL111905A (de)
NO (1) NO311868B1 (de)
NZ (1) NZ276285A (de)
PT (2) PT732928E (de)
WO (1) WO1995015760A1 (de)
ZA (1) ZA949663B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
ATE356113T1 (de) 1997-05-14 2007-03-15 Atherogenics Inc Probucolbernsteinsäureester zur hemmung der expression von vcam-1
ES2190592T3 (es) * 1997-06-24 2003-08-01 Aventis Pharma Inc Fenoles y tiofenoles alquil-4-sililheterociclicos como agentes antioxidantes.
US6133467A (en) * 1997-06-25 2000-10-17 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
AU7588498A (en) * 1997-06-25 1999-01-04 Hoechst Marion Roussel, Inc. 2,6-di-t-butyl-4-{ (dimethyl-4-methoxyphenylsilyl) -methyloxy}phenol and 2,6-di-t-butyl-4-{ (dimethyl-2-methoxy-phenylsilyl) -methyloxy}phenol
AU8282798A (en) 1997-07-01 1999-01-25 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
AU1911200A (en) * 1998-11-09 2000-05-29 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US6887712B1 (en) 1998-11-09 2005-05-03 Atherogenics, Inc. Methods and compositions to lower plasma cholesterol levels
US6821738B2 (en) 1999-01-20 2004-11-23 The Board Of Regents For Oklahoma State University Broad spectrum bio-detection of nerve agents, organophosphates, and other chemical warfare agents
CA2428753C (en) 2000-11-17 2013-05-21 Universita Degli Studi Di Cagliari Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US6960683B2 (en) 2002-07-12 2005-11-01 Atherogenics, Inc. Salt forms of poorly soluble probucol esters and ethers
US7173129B2 (en) 2003-06-06 2007-02-06 Athero Genics, Inc. Sulfonamide-substituted chalcone derivatives and their use to treat diseases
JP2007509054A (ja) * 2003-10-17 2007-04-12 アミリン・ファーマシューティカルズ,インコーポレイテッド 血管健康を促進するシリルフェノール
WO2005112914A2 (en) 2004-04-20 2005-12-01 Atherogenics, Inc. Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
EP2139320A4 (de) 2007-03-26 2010-09-08 Salutria Pharmaceuticals Llc Verfahren und zusammensetzungen von probucol-derivaten für die behandlung von diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE349046B (de) * 1966-12-23 1972-09-18 C Guevne
FR2230376A1 (en) * 1973-05-24 1974-12-20 Gueyne Jean Stable solutions of siloxanic polysilanols - prepd. by hydrolysis of a silane and having pharmaceutical activity
FR2308372A2 (fr) * 1975-04-21 1976-11-19 Cortial Produits pharmaceutiques contenant un compose organosilicie en tant qu'agent actif
US4670421A (en) * 1982-07-12 1987-06-02 American Cyanamid Company Antiatherosclerotic silanes
US4900757A (en) * 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
US5155250A (en) * 1990-07-05 1992-10-13 Merrell Dow Pharmaceuticals Inc. 2,6-di-alkyl-4-silyl-phenols as antiatheroscerotic agents
NZ238807A (en) * 1990-07-05 1994-03-25 Merrell Dow Pharma Bis[4-(2,6-dialkyl)phenol]silane derivatives and antiatherosclerotic compositions

Also Published As

Publication number Publication date
EP1468692B1 (de) 2006-04-26
DK0732928T3 (da) 2005-04-18
AU1049995A (en) 1995-06-27
ATE285238T1 (de) 2005-01-15
DE69434198D1 (de) 2005-01-27
DE69434720D1 (de) 2006-06-01
JPH09511222A (ja) 1997-11-11
EP1468693A2 (de) 2004-10-20
HU9601590D0 (en) 1996-08-28
IL111905A (en) 2001-04-30
DE69434720T2 (de) 2007-05-16
EP0732928A1 (de) 1996-09-25
HU220761B1 (hu) 2002-05-28
ES2263094T3 (es) 2006-12-01
PT1468692E (pt) 2006-09-29
ES2233937T3 (es) 2005-06-16
EP1468692A3 (de) 2004-11-03
HUT74015A (en) 1996-10-28
ZA949663B (en) 1995-08-15
IL111905A0 (en) 1995-03-15
EP1468692A2 (de) 2004-10-20
EP1468693A3 (de) 2004-11-03
CA2177968C (en) 2000-03-28
WO1995015760A1 (en) 1995-06-15
NO962415D0 (no) 1996-06-07
NO311868B1 (no) 2002-02-11
CN1092517C (zh) 2002-10-16
NO962415L (no) 1996-06-07
PT732928E (pt) 2005-03-31
CN1140995A (zh) 1997-01-22
CA2177968A1 (en) 1995-06-15
AU681731B2 (en) 1997-09-04
EP0732928B1 (de) 2004-12-22
DK1468692T3 (da) 2006-08-28
DE69434198T2 (de) 2005-12-29
NZ276285A (en) 2004-11-26

Similar Documents

Publication Publication Date Title
DE69434720D1 (de) Verwendung von 2,6-Dialkyl-4-Silyl-Phenol Derivaten zur Behandlung von Xanthom
NO179142C (no) 3-benzyliden-1-karbamoyl-2-pyrrolidon-analoger
DE69736642D1 (de) Heterocyclische Verbindungen, ihre Herstellung und Verwendung
NO308739B1 (no) Imidazolderivater samt medisinsk sammensetning og anti-HIV- sammensetning omfattende samme
LU91196I2 (fr) Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO).
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
EP0632031A4 (de)
ATE181066T1 (de) Zwischenverbindungen zur herstellung von thioalkylthio cephalosporinderivaten
NZ218243A (en) B-carboline derivatives and pharmaceutical compositions
SE8303913D0 (sv) Heterocykliska foreningar
ATE118346T1 (de) Verwendung von bis(4-hydroxyphenylthio)methan- derivaten zur behandlung von diabetes mellitus.
ATE215075T1 (de) Hydroxylamin-derivate mit anti-ischämischer wirkung und pharmazeutische zusammensetzungen diese enthaltend
ATE138914T1 (de) Indeno-d-pyrimidonverbindungen zur verwendung in der medizin
DE69320730D1 (de) Alkylendiaminderivate
ATE143591T1 (de) Verwendung von bis-(p- hydroxyphenylthio)methanderivaten zur hemmung der fortschreitenden entwicklung von insulinabhängingem diabetes mellitus
DK0532725T3 (da) Isoxazolderivater som lysfilterpræparater
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение
FI935399L (fi) N-substituerade azabicykloheptanderivat samt deras framstaellning och anvaendning

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1468692

Country of ref document: EP

REN Ceased due to non-payment of the annual fee